Sanbio Co., Ltd. (4592) Press Release
Consolidated Financial Results for the Three Months Ended April 30, 2026[Japanese GAAP]
Earlier from Sanbio
- SanBio Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation as a Therapeutic Agent for Improving Chronic Motor Paralysis from Traumatic Brain Injury
- SanBio Obtains Marketing Approval for “AKUUGO® Suspension for Intracranial Implantation” (INN: Vandefitemcel) as a Therapeutic Agent for Improving Chronic Motor Paralysis From Traumatic Brain Injury (TBI)
- SanBio: Announcement on Granting Stock Options (Share Acquisition Rights)
- SanBio: Notice regarding appointment of new corporate officers